Intensified Treatment of Tuberculous Meningitis in Adults: A Systematic Review and Meta-analysis
Abstract
Background: Tuberculous meningitis (TBM) remains the deadliest form of tuberculosis. Inadequate penetration of rifampicin and ethambutol into the brain and cerebrospinal fluid (CSF) may contribute to mortality. Over the last decade, research has focused on "intensified" treatment (higher-dose first-line drugs or addition of second-line drugs with good CSF penetration). This systematic review and meta-analysis evaluates the impact of intensified TBM treatment on mortality, disability, and safety.
Methods: A systematic literature search was conducted of clinical trials examining intensified TBM treatments compared with a rifampicin-based standard-of-care regimen in adults. Odds ratios (ORs) were calculated using a random-effects model with mortality as the primary outcome, with OR <1 indicating lower mortality. Disability and safety were examined as secondary outcomes. Subgroup analyses included (1) higher-dose rifampicin, (2) addition of fluoroquinolones, and (3) addition of linezolid.
Results: Ten trials meeting eligibility criteria, involving 1369 participants, were included. Higher-dose rifampicin (n = 1050; OR, 0.86; 95% CI, 0.54-1.35; P = .50), adjunctive fluoroquinolones (n = 1115; OR, 0.85; 95% CI, 0.56-1.27; P = .42), and linezolid (n = 79; OR, 0.73; 95% CI, 0.22-2.43; P = .61) did not significantly reduce TBM mortality. Due to heterogeneity in disability and safety endpoints, secondary outcomes could not be meta-analyzed.
Conclusions: Current clinical trial evidence…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 1,369 participants or records.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.